Clamycin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clamycin

Quick Facts

Property Description
Active ingredient Clarithromycin
Form Tablets, extended-release tablets, oral suspension
Pharmacological class Macrolide Antibiotic
Common use Combatting bacterial infections
Origin Semi-synthetic

Clamycin is a prescription-only medication, with the active ingredient being Clarithromycin. It is categorized within the macrolide antibiotic pharmacological class, an identity clinically recognized for its targeted antibacterial capabilities. This medication is designed to provide comprehensive treatment against susceptible bacterial pathogens.


Defining Clamycin: Composition and Class

Clamycin contains the compound Clarithromycin as its active ingredient, which is a single-component substance. Scientifically, it is classified as a macrolide antibiotic, a specific type of antibacterial agent. Clarithromycin is a semi-synthetic derivative; this modification improves its stability and absorption compared to earlier agents like Erythromycin. This distinction in structure contributes to its reliable function after oral route administration.


Clarithromycin's General Action and Therapeutic Purpose

The overall therapeutic purpose of Clarithromycin is the successful control and management of bacterial infections throughout the body. The active ingredient functions as a bacteriostatic agent, which acts by inhibiting the bacteria's ability to divide and multiply. This action of stopping population expansion provides the necessary intervention for the body's natural immune system to clear the remaining, disabled bacterial cells.


Available Forms and Administration Type

The active ingredient, Clarithromycin, is packaged in various oral formulations to suit different patient needs. These common preparations include standard film-coated tablets, specialized extended-release tablets, and powder for oral suspension. All preparations are intended for the oral route of administration. The extended-release version is functionally distinct because it is specifically designed to deliver the Clarithromycin slowly over time, aiming for more consistent drug levels and a reduced dosing frequency compared to immediate-release formulations.

Regulatory References

  1. WHO Essential Medicines List (Clarithromycin)
  2. NIH LiverTox (Clarithromycin)

What side effects are possible with Clamycin?

Serious Adverse Reactions and Contraindications

The most serious risk associated with this medicine is Clostridioides difficile-associated diarrhea (CDAD), which can lead to colitis that may be life-threatening. Official warnings state this risk can occur not only during therapy but also up to several months after the medicine has been discontinued. For a related drug (Clarithromycin), official regulatory communications advise caution in patients with heart disease due to a potential long-term risk of heart problems or death.

The medicine is contraindicated (must not be used) in individuals with a known history of hypersensitivity or allergy to clindamycin or lincomycin.


Reported Side Effects by System-Organ Class

Adverse reactions are classified by the affected body system, with some of the most commonly reported effects involving the Gastrointestinal System (e.g., diarrhea, nausea, vomiting, abdominal pain) and Skin and Subcutaneous Tissue (e.g., rash, itching, urticaria).

Other serious, but rare, safety concerns documented in regulatory information include: Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome, Anaphylaxis (a severe allergic reaction), and Hepatotoxicity (liver injury) evidenced by jaundice and abnormal liver function tests. Effects on the Blood and Lymphatic System such as transient neutropenia, leukopenia, and thrombocytopenia have also been reported.

Overdose and Emergency Response

Clamycin (Clarithromycin) overdose reports primarily document severe gastrointestinal manifestations. These commonly include abdominal pain, nausea, vomiting, and diarrhea. In cases of massive ingestion, official reports have documented severe systemic effects such as altered mental status and paranoid behavior.

The most serious outcomes are associated with the cardiovascular system. Overdose can lead to prolongation of the QT interval, which carries a critical risk of developing severe ventricular arrhythmias. These potentially life-threatening complications include ventricular tachycardia and the polymorphic arrhythmia known as Torsades de Pointes.

If an overdose is suspected, it is mandatory to seek immediate medical attention by contacting a poison control center or emergency services. The documented treatment is entirely symptomatic and supportive. Procedural measures may involve the prompt elimination of any unabsorbed drug, such as through gastric lavage.

The official labeling states that Clarithromycin concentrations are not expected to be reduced significantly by hemodialysis or peritoneal dialysis. No specific pharmacological antidote is known. A specific consideration exists regarding the concomitant use of Clarithromycin and colchicine, where the risk of colchicine toxicity is increased, especially for elderly patients and those with existing renal insufficiency. Close monitoring for signs of such toxicity is officially required.

Therapeutic Uses of Clamycin

Clamycin (Clarithromycin) is used in situations involving certain distressing symptoms associated with susceptible bacterial infections, applied across domains where additional symptomatic support is needed. It is generally used for conditions presenting with systemic or localized discomfort, assisting with maintaining functional stability during symptomatic periods.

Easing Symptoms of Acute Bacterial Infections

Clamycin is commonly used across conditions presenting with acute episodes and is relevant for managing symptom clusters that may become intense or disruptive. It is applied in addressing conditions involving inflammatory or irritative processes in the respiratory tract (such as pneumonia and bronchitis), the sinuses, the skin, and the middle ear. The core therapeutic benefit contributes to easing the overall symptom load, including symptoms related to physical discomfort like fever, inflammation, and persistent cough. Clamycin is applied in clinical settings that involve acute or unstable symptom patterns, which supports the patient during difficult episodes by easing distress related to the infection.

The primary goal is to provide supportive relief during symptomatic phases where additional symptomatic support is needed.

Specialized Support and Pathogen Management

This medication is commonly used as part of a combination regimen for managing conditions involving the Helicobacter pylori pathogen (related to duodenal ulcers), and may assist with maintaining functional stability by supporting the process of clearing the pathogen. Clamycin is also considered a critical therapeutic alternative for patients with penicillin hypersensitivity, and is utilized in specialized prophylaxis and treatment protocols, such as providing support against opportunistic infections like Disseminated Mycobacterium avium Complex (MAC) in vulnerable patient populations.


Quick Fact: Relief for Symptomatic Discomfort
Relief Focus May assist with reducing fever, supporting the easing of cough severity, and contributing to the decrease of associated pain.
Target Conditions Conditions presenting with systemic or localized discomfort, including acute respiratory and skin infections.
Primary Benefit Helps improve day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Clamycin

Eligibility for Clamycin (Clarithromycin) is strictly defined by official regulatory documents based on patient status, co-existing conditions, and age. The medication is a prescription-only macrolide antibiotic.

Absolute Contraindications

Clamycin is strictly contraindicated and must not be used by individuals with a known hypersensitivity to Clarithromycin or any macrolide antibiotic. Non-eligibility also applies to patients with pre-existing congenital or acquired QT prolongation or a history of ventricular arrhythmia.

Use is prohibited for patients with severe hepatic failure combined with renal impairment, or uncorrected low potassium/magnesium levels (hypokalaemia/hypomagnesaemia).

Age and Organ Function Restrictions

Population Group Eligibility Status (Regulatory Basis)
Adults and Adolescents ( ge 12 years) Generally allowed for standard use.
Children (under 12 years) Use of oral suspension is typically approved; extended-release tablets are usually not recommended.
Renal Impairment Use is restricted and necessitates mandatory dose adjustment.
Pregnancy/Lactation Generally not recommended, especially in the first trimester of pregnancy or while breastfeeding.

These rules establish the mandatory boundaries for eligibility, ensuring the medicine is only used by populations documented as having an acceptable risk profile under labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clamycin (clarithromycin) is a potent CYP3A4 inhibitor and can significantly alter the metabolism and concentration of many other medications. Consult your healthcare provider about all medicines, supplements, and herbal products you are taking before starting Clamycin.


Serious and Potentially Life-Threatening Interactions

Co-administration with Clamycin can lead to dangerously high levels of certain drugs, increasing the risk of severe side effects, including QT interval prolongation and rhabdomyolysis. Avoid using Clamycin with the following:

  • Statins (e.g., simvastatin, lovastatin) due to increased risk of muscle toxicity.
  • Ergot alkaloids (e.g., ergotamine, dihydroergotamine) for treating migraines, as this can cause acute ergotism.
  • Pimozide or cisapride due to a significantly increased risk of severe cardiac arrhythmias.

Other Notable Interactions

Drug Class/Example Mechanism of Interaction
Oral Anticoagulants (e.g., Warfarin) Enhanced anticoagulant effect; monitor **INR** closely.
Oral Hypoglycemics (e.g., Glyburide, Insulin) Increased risk of **hypoglycemia** (low blood sugar).
Calcium Channel Blockers (e.g., Verapamil, Amlodipine) Increased risk of hypotension and bradyarrhythmia.
Colchicine Increased systemic exposure to colchicine, increasing toxicity.

Note: This list is not exhaustive. Dosage adjustments may be necessary for drugs like theophylline, carbamazepine, and digoxin. Do not stop or change the dose of any medication without medical advice. (Word count: 198)

Mechanism of Action

How Clamycin Works: Mechanism of Action

Clamycin exerts its action as a highly selective inhibitor by targeting the essential protein synthesis machinery within susceptible bacteria. Specifically, the molecule binds to a site on the 50S ribosomal subunit, which is a large complex required for building bacterial proteins. This binding prevents the ribosome from completing its catalytic steps, namely peptidyl transferase activity and translocation.

This molecular interaction triggers a mechanistic cascade where the bacteria are unable to assemble the functional proteins necessary for cell division, structure maintenance, and metabolic processes. The resulting intracellular consequence is the disruption of the bacterial replication cycle. This targeted pathway interference leads to a core physiological effect of modulating the dynamics within the targeted pathway and blocking the advancement of the bacterial growth cycle. Clamycin's ability to penetrate certain host cells and accumulate at the site of activity ensures its effective concentration near the ribosomal target.

Dosage and Administration Information

How to Use Clamycin (Clarithromycin) — Administration Guidelines

Clamycin, also known as clarithromycin, is administered according to specific procedural protocols based on the formulation and patient requirements.


Administration Routes and Forms

Category Administration Instructions
Route of Administration Oral (tablets, granules for suspension) or Intravenous (IV) (injection).
Standard Dosing Schedule Immediate-Release Forms (IR/Suspension): Typically 250 mg or 500 mg per dose. Extended-Release Tablets (ER): Typically 1000 mg dose. IV: Typically 500 mg per dose.
Frequency Twice daily (every 12 hours) for IR forms and IV infusion. Once daily for ER tablets.

Preparation and Procedural Rules

Category Specific Procedural Conditions
Timing with Meals IR Forms: May be taken with or without food. ER Tablets: Must be taken with food.
Preparation Requirements Oral Suspension: Reconstitute granules with the specified amount of water; shake well before each use. IV Powder: Requires initial reconstitution followed by further dilution with an approved IV fluid (e.g., 5% Dextrose) before administration.
Special Handling ER Tablets must be swallowed whole; they must not be crushed or chewed. IV Infusion must be administered slowly over at least 60 minutes; rapid administration is forbidden.

Population-Specific Rules

For pediatric patients, dosing is typically determined by body weight (e.g., 7.5 mg/kg) using the oral suspension. For adults diagnosed with severe renal impairment (creatinine clearance < 30 mL/min), the total daily dose is reduced by half to ensure appropriate use. If a dose is missed, the standard procedure is to take it as soon as remembered unless it is almost time for the next scheduled dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Clamycin

Evidence for Use in Acute Bacterial Infections

Research exploring how symptoms change over time in patients with acute bacterial infections was evaluated in numerous short-term randomized controlled trials (RCTs). These studies were designed to examine Clamycin's application in conditions such as bronchitis, sinus, ear, and community-acquired pneumonia. Researchers monitored outcomes related to physical discomfort and outcomes describing episodic or acute changes.

Studies conducted during periods of increased symptom activity examined measures related to clinical symptom change and microbiological status. Findings describe patterns related to short-term changes in bacterial status and the evolution of measured symptoms like fever and cough. However, the evidence base is limited by the challenge of increasing macrolide resistance, which may affect the measured outcomes in different regions.


Evidence for Specialized Pathogen Management

Clamycin was evaluated in research contexts involving pathogens like Helicobacter pylori and Disseminated Mycobacterium avium Complex (MAC). Research examined its application as part of combination drug regimens.

For H. pylori, studies monitored measured eradication rates, confirmed by specific laboratory tests performed at least four weeks after treatment. For MAC, research explored outcomes related to microbiological suppression and the evaluation of prophylactic strategies for disseminated disease in highly vulnerable patient populations. What remains uncertain is the consistency of the evidence for H. pylori eradication, as success was associated with variability in the measured eradication rate across different regions.


Studies on Long-Term Outcomes and Follow-up

Research has explored outcomes over a considerably longer duration, tracking patients for up to 10 years after a single, short course of Clamycin was studied for an unrelated infection. This research focused on long-term health outcomes in a specific population of adults with pre-existing stable coronary heart disease (CHD).

These studies monitored outcomes over the long term, including all-cause mortality and cardiovascular mortality. Findings related to these long-term effects were mixed across the available evidence base. The biological mechanism that may explain any potential long-term outcome is not fully established, and research is ongoing regarding the clinical relevance of these findings in the general population.

Key Studies & References

  1. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV

Frequently Asked Questions (FAQ)

Common questions about Clamycin (FAQ)


Q: Can Clamycin cause nausea or stomach discomfort?

Official safety documents indicate that side effects affecting the gastrointestinal system are commonly reported with this medicine. These effects may include nausea, vomiting, diarrhea, and abdominal pain. Concerns about persistent or severe discomfort are usually best addressed by consulting a healthcare professional.

Q: What happens if a dose of Clamycin is missed?

Regulatory guidance suggests that a missed dose should be taken as soon as you remember it. However, if it is almost time for your next scheduled dose, the official advice is to skip the missed dose and continue with your regular schedule. The advice to skip the dose, if the next dose is due soon, is related to maintaining the intended spacing between doses.

Q: Is Clamycin generally safe for older adults (the elderly)?

Regulatory documents advise that caution should be used when prescribing this medication to older adults. This is because older patients may have underlying conditions, such as reduced kidney function, which could affect how the medicine works or increase the chance of experiencing side effects.

Q: Is there any research looking at Clamycin's use in children?

Yes, clinical trials have specifically examined the use of the oral suspension formulation for children in treating certain approved infections, such as acute otitis media (middle ear infection). Official documents confirm the approval of the oral suspension for use in children under 12 years of age.

Q: Can Clamycin affect a person's mood or cause anxiety?

Post-marketing safety data from official sources includes reports of psychiatric and nervous system effects. These can include dizziness, anxiety, insomnia (difficulty sleeping), and nightmares. Unusual changes in mood or behavior are typically circumstances where consultation with a healthcare professional is appropriate.

Q: What is the risk of developing resistance to Clamycin?

Regulatory documents acknowledge that, as with any antibiotic, the possibility exists for the emergence of drug-resistant bacteria. This means the bacteria can change over time and may no longer be effectively inhibited by the medicine. This is a common phenomenon with antibiotic use in general.

Q: How quickly should I expect Clamycin to start working?

Pharmacokinetic studies indicate that the medicine is rapidly absorbed after you take it orally. Generally, steady-state concentrations—the levels needed for therapeutic effect—are attained in the bloodstream within approximately two to three days of twice-daily dosing.

Q: Are there any major diet restrictions or foods to avoid while on Clamycin?

Official sources specifically indicate that consuming grapefruit juice can influence the time it takes for the drug to reach its highest level in your body. Regulatory documents indicate that the timing of administration relative to food can differ based on the specific formulation of Clamycin being used.

Q: Can people with liver problems use Clamycin?

Regulatory documents advise that caution should be used when administering this drug to patients with existing liver issues. Furthermore, its use is strictly prohibited in individuals who have severe liver failure combined with kidney impairment.

Q: Is Clamycin considered a long-term treatment or is it usually short-term?

The drug is most often prescribed for short-term treatment regimens, commonly lasting between 7 and 14 days for standard infections. However, official documents describe that for certain specific, chronic infections, specialized treatment protocols may require longer durations of use.

Q: Why is Clamycin sometimes prescribed for conditions that seem unrelated?

The approved uses of this medication are based on its ability to inhibit a wide variety of susceptible pathogens. Regulatory indications list its use in treating common respiratory infections, as well as highly specific organisms like Helicobacter pylori (H. pylori) and Mycobacterium avium.

Q: Can Clamycin cause dizziness or affect driving?

Official safety profiles report dizziness as a potential side effect of the medication. Official regulatory guidance indicates that if dizziness is experienced, it has the potential to affect a person's ability to drive or operate machinery.

Q: What are the signs of a severe or serious reaction to Clamycin?

Official warnings highlight signs that may indicate a severe reaction, such as yellowing of the skin or eyes (jaundice), dark urine, severe abdominal pain, blood or mucus in diarrhea, or signs of a serious skin reaction like blistering or peeling skin. The appearance of any of these signs is a circumstance where seeking medical attention is required.

Q: Is it normal for Clamycin to cause changes in taste or smell?

Yes, official side effect listings confirm that a change in the sense of taste (dysgeusia) is a commonly reported side effect, a phenomenon often associated with this class of medicine. Changes in the sense of smell are also sometimes reported in the official safety data.

Q: How long does Clamycin stay in your system after the last dose?

Pharmacokinetic data from official sources indicates that the time it takes for half of the drug to be eliminated, known as the half-life, is approximately 3 to 7 hours, depending on the administered dose.

Q: Do studies suggest Clamycin is effective for its approved use?

The medication is approved by regulatory bodies for its listed indications based on clinical evidence. This evidence demonstrated its ability to resolve the conditions or successfully eliminate the target bacteria, as described in the official documents.

Q: Is there a maximum time someone can stay on Clamycin?

The required duration of use is specific to the condition being treated, with many regimens not lasting longer than 7 to 14 days. However, specialized treatment plans, such as those targeting specific chronic infections, may extend for several months, as documented in regulatory materials.

Q: Can Clamycin be prescribed for people with heart problems?

Regulatory documents state that use is prohibited for individuals with a history of certain heart issues, specifically QT prolongation or ventricular arrhythmia. Official warnings advise prescribers to use caution in all patients with heart disease due to potential risks.

Q: Why do some people report feeling better after just a few days on Clamycin?

Clinical studies show that the medication begins to reach a consistent, therapeutic concentration in the bloodstream within approximately two to three days of starting therapy. This period often corresponds to the time when patients typically begin to perceive an improvement in their symptoms.

Q: Does Clamycin affect sleep patterns?

Yes, official safety data lists insomnia (difficulty falling or staying asleep) as a reported side effect of the medication.

Q: What are the main reasons a doctor might choose Clamycin over other options?

Official regulatory documents indicate that its role is often determined by its wide spectrum of activity against a broad range of both typical and atypical bacteria. It may be chosen for infections caused by specific pathogens where other common antibiotics are not considered appropriate.

Q: Are there specific instructions for the non-directive timing of taking Clamycin (e.g., morning vs. evening)?

The required frequency for the immediate-release forms is twice daily (every 12 hours), according to official administration guidelines. This means the doses should be spaced out across the day, but specific times like morning or evening are not universally mandated for all patients.

How should Clamycin be stored and disposed of?

Storage and Handling

Clarithromycin tablets must be stored at controlled room temperature, specifically between 68°F and 77°F (20°C and 25°C), and must be protected from light. The medicine should be kept in its original container with the cap tightly closed and stored out of the sight and reach of children.

The mixed oral suspension requires different handling; it must not be refrigerated. The liquid is stable for 14 days and any unused portion must be discarded after this period. Unmixed granules should be stored below 77°F (25°C).

Disposal Instructions

Unused or expired Clarithromycin must be disposed of according to official regulatory guidelines, typically through drug take-back programs. If these are unavailable, the medication should be mixed with an undesirable substance like dirt or coffee grounds, sealed in a bag, and placed in the household trash. Disposal must always align with local medicinal waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clamycin found in:

A-Z Index: